AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18344941 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 79
Study 17162992 — intervention group
Group type: EXPERIMENTAL
Intervention: Home CPAP titration (3 nights)
Number of subjects: 200
Study 17162992 — intervention group
Group type: COMPARATOR
Intervention: In-laboratory CPAP titration (1 night)
Number of subjects: 200
Study 14592587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 34
Study 14592587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11071801 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (on-site coronary angioplasty or emergency air-ambulance transfer for bypass grafting surgery)
Number of subjects: 148
Study 11071801 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (persistent medical treatment)
Number of subjects: 148
Study 8828077 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet (supplemental dietary arginine, canola oil, and trace elements)
Number of subjects: 0
Study 8828077 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 0
Study 1473420 — intervention group
Group type: COMPARATOR
Intervention: Conventional scissors excision with ligation (Group A; n = 16)
Number of subjects: 49
Study 1473420 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy excision without ligation (Group B; n = 33)
Number of subjects: 49
Study 1473420 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 6381006 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) using the Mill-Hill Infuser
Number of subjects: 12
Study 6381006 — intervention group
Group type: COMPARATOR
Intervention: Multiple injections (MI) using the Medi-Jector
Number of subjects: 12
Study 30807280 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer‐NoGo
Number of subjects: 81
Study 30807280 — intervention group
Group type: COMPARATOR
Intervention: Beer‐Go
Number of subjects: 81
Study 30807280 — intervention group
Group type: COMPARATOR
Intervention: Oddball
Number of subjects: 81
Study 30807280 — intervention group
Group type: COMPARATOR
Intervention: BAI
Number of subjects: 81
Study 29332645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-meal administration of Rifampicin
Number of subjects: 52
Study 29332645 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-meal administration of Rifampicin
Number of subjects: 52
Study 29332645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-meal administration of Pyrazinamide
Number of subjects: 52
Study 29332645 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-meal administration of Pyrazinamide
Number of subjects: 52
Study 28040121 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual misoprostol 400 μg
Number of subjects: 120
Study 28040121 — intervention group
Group type: COMPARATOR
Intervention: intravenous oxytocin 20 units
Number of subjects: 120
Study 24443547 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP-based combination antiretroviral therapy (cART)
Number of subjects: 219
Study 24443547 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP-based cART
Number of subjects: 219
Study 21414137 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary 3-implant overdentures with splinted attachment system
Number of subjects: 40
Study 21414137 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary 3-implant overdentures with unsplinted attachment system
Number of subjects: 40
Study 21414137 — intervention group
Group type: COMPARATOR
Intervention: Conventional maxillary dentures (pre-treatment)
Number of subjects: 40
Study 21414137 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary 3-implant overdentures (after 1 year)
Number of subjects: 40
Study 21414137 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary 3-implant overdentures (after 2 years)
Number of subjects: 40
Study 20470365 — intervention group
Group type: EXPERIMENTAL
Intervention: Counsellors Contact Caregivers (CCC) intervention, where general practitioners recommend family counsellors who actively contact caregivers.
Number of subjects: 110
Study 20470365 — intervention group
Group type: COMPARATOR
Intervention: No specific control intervention mentioned, but 29 family members (30%) had no personal contact or only one personal contact (33 cases, 34%).
Number of subjects: 110
Study 18158878 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple treatment plus Lactobacillus casei strain Shirota
Number of subjects: 64
Study 18158878 — intervention group
Group type: COMPARATOR
Intervention: Triple treatment alone (control)
Number of subjects: 64
Study 16491680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (posters and lectures promoting participation in physical activity for 12 weeks)
Number of subjects: 366
Study 16491680 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 366
Study 11791032 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 105
Study 11791032 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10 mg)
Number of subjects: 105
Study 11791032 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan + Quinapril
Number of subjects: 105
Study 11791032 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine + Quinapril
Number of subjects: 105
Study 11791032 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10 mg) followed by Losartan (50 mg) or Amlodipine (5 mg)
Number of subjects: 105
Study 10416748 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% carbogen for 7 minutes
Number of subjects: 5
Study 10416748 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen for 7 minutes
Number of subjects: 5
Study 10416748 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased IOP to 50 mm Hg
Number of subjects: 5
Study 10416748 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol (betoptic)
Number of subjects: 5
Study 10416748 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol (timoptic)
Number of subjects: 5
Study 7575714 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg/day)
Number of subjects: 22
Study 7575714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7575714 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 22
Study 2205799 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass surgery
Number of subjects: 838
Study 6118859 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 100
Study 6118859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6118859 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine
Number of subjects: 100
Study 30993696 — intervention group
Group type: COMPARATOR
Intervention: NaOCl
Number of subjects: 60
Study 30993696 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl/HEDP
Number of subjects: 60
Study 30993696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 28846122 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh)
Number of subjects: 50
Study 28846122 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (control)
Number of subjects: 50
Study 25616647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab 400 mg weekly added to standard radiochemotherapy followed by 400 mg biweekly after twelve weeks
Number of subjects: 149
Study 25616647 — intervention group
Group type: COMPARATOR
Intervention: Standard radiochemotherapy
Number of subjects: 149
Study 25616647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab in patients with residual tumour
Number of subjects: 149
Study 25616647 — intervention group
Group type: COMPARATOR
Intervention: Standard radiochemotherapy in patients with residual tumour
Number of subjects: 149
Study 25616647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab in patients without residual tumour
Number of subjects: 149
Study 25616647 — intervention group
Group type: COMPARATOR
Intervention: Standard radiochemotherapy in patients without residual tumour
Number of subjects: 149
Study 25616647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab in MGMT non-methylated patients with residual tumour
Number of subjects: 149
Study 25616647 — intervention group
Group type: COMPARATOR
Intervention: Standard radiochemotherapy in MGMT non-methylated patients with residual tumour
Number of subjects: 149
Study 23823078 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (ivB)
Number of subjects: 0
Study 21184977 — intervention group
Group type: EXPERIMENTAL
Intervention: Hindi version of the Quality of Life for Eating Disorders questionnaire (QOL ED‐H)
Number of subjects: 95
Study 21184977 — intervention group
Group type: COMPARATOR
Intervention: English version of the Quality of Life for Eating Disorders questionnaire (QOL ED)
Number of subjects: 95
Study 19299777 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg tablet
Number of subjects: 40
Study 19299777 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 40
Study 17719327 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.5 pmol/kg/min) as a continuous infusion beginning 12 hours before CABG and continuing for 48 hours
Number of subjects: 20
Study 17719327 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy at the discretion of the surgeon
Number of subjects: 20
Study 17719327 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.5 pmol/kg/min) as a continuous infusion
Number of subjects: 20
Study 14744921 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg twice daily for 4 weeks
Number of subjects: 25
Study 14744921 — intervention group
Group type: COMPARATOR
Intervention: celecoxib 200 mg/d for 4 weeks
Number of subjects: 25
Study 14744921 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg twice daily at peak
Number of subjects: 25
Study 14744921 — intervention group
Group type: COMPARATOR
Intervention: celecoxib 200 mg/d at peak
Number of subjects: 25
Study 14744921 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg twice daily for 24 hours
Number of subjects: 25
Study 14744921 — intervention group
Group type: COMPARATOR
Intervention: celecoxib 200 mg/d for 24 hours
Number of subjects: 25
Study 11799264 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dialysis treatment time by 2 h and reduced dry weight (group 1)
Number of subjects: 21
Study 11799264 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dialysis treatment time by 2 h without changing dry weight (group 2)
Number of subjects: 21
Study 11799264 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dry weight without changing dialysis treatment time (group 3)
Number of subjects: 21
Study 9713730 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl/pancuronium
Number of subjects: 20
Study 9713730 — intervention group
Group type: COMPARATOR
Intervention: Midazolam/halothane/fentanyl/pancuronium
Number of subjects: 20
Study 7975783 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha-2a (IFN alpha-2a) at a dosage of 3 x 3 million units per week for 1 year
Number of subjects: 40
Study 7975783 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alpha-2a (IFN alpha-2a)
Number of subjects: 40
Study 7975783 — intervention group
Group type: COMPARATOR
Intervention: Dosis escalation after 8 and 16 weeks in serological non-responders
Number of subjects: 40
Study 2596943 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention strategy (monthly mailed informational packets and monthly to quarterly telephone contacts)
Number of subjects: 90
Study 2596943 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 90
Study 2596943 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 90
Study 1122924 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat emulsion infusion
Number of subjects: 12
Study 1122924 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 12
Study 1122924 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exercise
Number of subjects: 12
Study 31550947 — intervention group
Group type: EXPERIMENTAL
Intervention: APT Triathlon PS TKA
Number of subjects: 60
Study 31550947 — intervention group
Group type: COMPARATOR
Intervention: MBT Triathlon PS TKA
Number of subjects: 60
Study 28118788 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic HH repair
Number of subjects: 36
Study 28118788 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopic HH repair
Number of subjects: 36
Study 28118788 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic HH repair with mesh positioning
Number of subjects: 36
Study 28118788 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic HH repair without mesh positioning
Number of subjects: 36
Study 28118788 — intervention group
Group type: COMPARATOR
Intervention: 2D laparoscopic HH repair with mesh positioning
Number of subjects: 36
Study 26167618 — intervention group
Group type: EXPERIMENTAL
Intervention: ART within 4 weeks of starting TB treatment (Arm-1)
Number of subjects: 642
Study 26167618 — intervention group
Group type: EXPERIMENTAL
Intervention: ART after the intensive phase of TB treatment (Arm-2)
Number of subjects: 642
Study 26167618 — intervention group
Group type: COMPARATOR
Intervention: ART after completing TB treatment (Arm-3)
Number of subjects: 642
Study 26167618 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Arm-1 and Arm-2
Number of subjects: 642
Study 26167618 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Arm-3 and Arm-2
Number of subjects: 642
Study 22886805 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-navigated MIS anterior approach
Number of subjects: 75
Study 22886805 — intervention group
Group type: COMPARATOR
Intervention: Conventional posterolateral approach
Number of subjects: 75
Study 21301346 — intervention group
Group type: EXPERIMENTAL
Intervention: lotrafilcon A (Dk, 140)
Number of subjects: 29
Study 21301346 — intervention group
Group type: EXPERIMENTAL
Intervention: balafilcon A (Dk, 91)
Number of subjects: 29
Study 21301346 — intervention group
Group type: EXPERIMENTAL
Intervention: galyfilcon A (Dk, 60)
Number of subjects: 29
Study 21301346 — intervention group
Group type: EXPERIMENTAL
Intervention: senofilcon A (Dk, 103)
Number of subjects: 29
Study 21301346 — intervention group
Group type: COMPARATOR
Intervention: Control eye (no lens)
Number of subjects: 29
Study 19602507 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial vein surgery and compression
Number of subjects: 500
Study 19602507 — intervention group
Group type: COMPARATOR
Intervention: Compression alone
Number of subjects: 500
Study 16728248 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound activation with EDTA irrigation for 30 seconds before etching procedure
Number of subjects: 24
Study 16728248 — intervention group
Group type: COMPARATOR
Intervention: Control group treated using the etching procedure
Number of subjects: 24
Study 15374576 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease states derived from PANSS scores
Number of subjects: 663
Study 11194687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50 micrograms)
Number of subjects: 61
Study 11194687 — intervention group
Group type: COMPARATOR
Intervention: Intracervical dinoprostone gel
Number of subjects: 61
Study 11194687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 61
Study 9562232 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MPA) 2 x 1 g/day during peritoneal dialysis
Number of subjects: 5
Study 9562232 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MPA) 2 x 1 g/day without peritoneal dialysis
Number of subjects: 5
Study 8201376 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (BRT)
Number of subjects: 45
Study 8201376 — intervention group
Group type: COMPARATOR
Intervention: No Brachytherapy (no-BRT)
Number of subjects: 45
Study 2440455 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg midodrin hydrochloride administered intravenously
Number of subjects: 12
Study 2440455 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg midodrin hydrochloride as drinking solution
Number of subjects: 12
Study 2440455 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg midodrin hydrochloride as tablet (Gutron)
Number of subjects: 12
Study 29649996 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation for 12 weeks
Number of subjects: 60
Study 29649996 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study 27034316 — intervention group
Group type: EXPERIMENTAL
Intervention: Twinky Star Flow (Voco, Cuxhaven, Germany)
Number of subjects: 30
Study 27034316 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract Flow (Dentsply, Konstanz, Germany)
Number of subjects: 30
Study 27034316 — intervention group
Group type: EXPERIMENTAL
Intervention: R&D Series Nova Compomer Flow (Imicryl, Konya, Turkey)
Number of subjects: 30
Study 24860256 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg kg(‐1), remifentanil 0.30 μg kg min(‐1), and sevoflurane 1.0 MAC
Number of subjects: 83
Study 24860256 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1.5 mg kg(‐1), remifentanil 0.30 μg kg min(‐1), and rocuronium 0.45 mg kg(‐1)
Number of subjects: 83
Study 24860256 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SEVO and MR)
Number of subjects: 83
Study 22863096 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic cheese containing Lactobacillus plantarum Tensia at a concentration of 9.6 log cfu/g for 30 consecutive days.
Number of subjects: 0
Study 22863096 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic cheese with a daily dose of 10.3 or 8.17 log cfu/serving for 3 weeks.
Number of subjects: 0
Study 22863096 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular semihard Edam-type cheese with probiotic additive at a daily dose of 50g or in excess (100g) and with a probiotic daily dose of 10 log cfu for 3 weeks.
Number of subjects: 0
Study 22863096 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic cheese consumption confirmed presence of the ingested probiotic strain in feces.
Number of subjects: 0
Study 20139430 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinagolide 50 microg/day
Number of subjects: 182
Study 20139430 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinagolide 100 microg/day
Number of subjects: 182
Study 20139430 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinagolide 200 microg/day
Number of subjects: 182
Study 20139430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 20139430 — intervention group
Group type: EXPERIMENTAL
Intervention: All quinagolide groups combined
Number of subjects: 182
Study 20139430 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinagolide
Number of subjects: 182
Study 18672532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent therapy (8-week on/8-week off)
Number of subjects: 86
Study 15903385 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐minute lower‐body stretching protocol (S)
Number of subjects: 10
Study 15903385 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets of a leg press exercise using 90% of the subjects' previously determined 1 repetition maximum (P)
Number of subjects: 10
Study 15903385 — intervention group
Group type: COMPARATOR
Intervention: 10 minutes of quiet sitting (C)
Number of subjects: 10
Study 14625133 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mixture (25% insulin lispro and 75% NPL) plus metformin (Mix25+M)
Number of subjects: 597
Study 14625133 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide plus metformin (G+M)
Number of subjects: 597
Study 14625133 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mixture (Mix25+M)
Number of subjects: 597
Study 11106203 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine exposure at 0.5 ppm
Number of subjects: 7
Study 11106203 — intervention group
Group type: COMPARATOR
Intervention: Control exposure at 0 ppm
Number of subjects: 7
Study 9485980 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% propofol
Number of subjects: 110
Study 9485980 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% propofol
Number of subjects: 110
Study 8370356 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (nisoldipine) administered before or during ischaemia
Number of subjects: 25
Study 8370356 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 25
Study 8370356 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 25
Study 3523396 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (100 mg)
Number of subjects: 20
Study 3523396 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (150 mg)
Number of subjects: 20
Study 3523396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3523396 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluradoline (450 mg)
Number of subjects: 20
Study 29436172 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/wk testosterone cypionate
Number of subjects: 31
Study 29436172 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/wk testosterone cypionate
Number of subjects: 31
Study 29436172 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/wk testosterone cypionate
Number of subjects: 31
Study 29436172 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 31
Study 27510295 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1 mg/kg/day
Number of subjects: 90
Study 27510295 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% normobaric oxygen with mask, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
Number of subjects: 90
Study 27510295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 27510295 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 90
Study 27510295 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen
Number of subjects: 90
Study 24341963 — intervention group
Group type: EXPERIMENTAL
Intervention: Folder support intervention
Number of subjects: 241